RecruitingNCT04882839
Psilocybin-assisted therapy for severe OCD
About this title
Read the official source — NCT04882839This study evaluates the safety and effectiveness of psychotherapy for people with OCD.
Interventional studyAges 18–65Israel
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of psychotherapy for people with OCD.
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- BeershebaSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 25, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 15
- Sponsor
- Beersheva Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- COMBINATION_PRODUCT
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Israel
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04882839
- Official title
Show the full official title
Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Beersheba
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of psychotherapy for people with OCD.
Who is behind this study?
The study sponsor is Beersheva Mental Health Center, a hospital or academic medical center.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
